SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

A project grown out of the community's love and passion for the weed culture. Launched around early 2025, $weedcoin, “Like Bitcoin but way higher,” emphasizes its alignment with cannabis culture and a laid-back vibe. Unlike other Weed communities, this project leans heavily into community engagement over technical utility, aiming to build a “stoner community” through social media presence and decentralized governance. We also aim to focus on onboarding web2 businesses and users onto web3 through the token.

Weedcoin

WEEDCOIN is trending following a retail frenzy fueled by discussions around recent federal cannabis reclassification, seen as a significant catalyst for the sector. The community highlights WEEDCOIN as the primary beneficiary and a leading cultural play within the Solana ecosystem, positioning it as an on-chain alternative to traditional pharmaceutical models. Sentiment emphasizes its potential for substantial growth as the "Green Wave" gains momentum.

SSgA Active Trust - SPDR Dow Jones Industrial Average ETF

The SPDR Dow Jones Industrial Average ETF ($DIA) is actively debated as strong US economic data, including robust GDP and softening inflation, fuels optimism for a year-end rally. However, community sentiment is split, with many cautioning against "inorganic" holiday trading and potential global liquidity shifts, while others see DIA as an old economy barometer confirming broader market strength or weakness.

What is Amp?  Amp is described as the new digital collateral token offering instant, verifiable assurances for any kind of value transfer. Using Amp, networks like Flexa can quickly and irreversibly secure transactions for a wide variety of asset-related use cases.  How does Amp work?  Amp claims to offer a straightforward but versatile interface for verifiable collateralization through a system of collateral partitions and collateral managers. Where collateral partitions can be designated to collateralize any account, application, or even transaction, and carry balances which are directly verifiable on the Ethereum blockchain, collateral managers are smart contracts that can lock, release, and redirect collateral in these partitions as needed in order to support value transfer activities. Amp supports a wide variety of use cases for collateralization, and also introduces the concept of predefined partition strategies, which can enable special capabilities such as collateral models through which tokens can be staked without ever leaving their original address.

AMP Token

AMP Token is actively trending as discussions focus on its real-world utility through Flexa's expanding merchant network, enabling crypto payments at major retailers like Chipotle and Nordstrom. This visibility fuels optimism among long-term holders for future adoption and significant price recovery, contrasting with skepticism from those wary of past volatility and downward price trends. The community remains divided, debating whether current momentum signals a sustained uptrend or another fleeting pump.

Cadrenal Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in developing novel therapy. It develops tecarfarin, a novel therapy with orphan drug indication, designed for the prevention of systemic thromboembolism of cardiac origin in patients with end-stage renal disease and atrial fibrillation. The company was founded by Quang X. Pham and Matthew K. Szot on January 25, 2022 and is headquartered in Ponte Vedra, FL.

Cadrenal Therapeutics Inc

Cadrenal Therapeutics, Inc.

Cadrenal Therapeutics is gaining attention for its expanding anticoagulation pipeline, highlighted by recent acquisitions and significant progress on its lead candidate, tecarfarin, including manufacturing readiness and a collaboration with Abbott. This "quiet expansion" is sparking community interest, with many anticipating a breakout given its low float and regulatory designations. However, skepticism persists among some regarding the company's financial stability and potential dilution.

TotalEnergies SE is a global integrated energy company, which engages in the production of oil and biofuels, natural gas and green gases, renewables and electricity. It operates through the following business segments: Exploration & Production, Integrated LNG, Integrated Power, Refining & Chemicals, and Marketing & Services. The Exploration & Production segment encompasses oil and natural gas exploration and production activities. The Integrated LNG segment includes the integrated gas chain (including upstream and midstream LNG activities) as well as biogas, hydrogen and gas trading activities. The Integrated Power segment involves in the generation, storage, electricity trading and B2B-B2C distribution of gas and electricity. The Refining & Chemicals segment engages in the activities of refining, petrochemicals and specialty chemicals. This segment also includes the activities of oil supply, trading and marine shipping. The Marketing & Services segment includes the global activities of supply and marketing in the field of petroleum products. The company was founded on March 28, 1924 and is headquartered in Courbevoie, France.

TotalEnergies SE

Total Energies

TotalEnergies is trending as it expands its clean energy footprint with significant long-term deals, including powering Google's data centers, and actively pursues high-potential deepwater oil and gas exploration projects. The community is discussing its compelling dividend yield and strategic portfolio transformation, alongside its potential consideration for a New York listing to enhance valuation.

Parker-Hannifin Corp. engages in the manufacture of motion and control technologies and systems. It operates through the Diversified Industrial and Aerospace Systems segments. The Diversified Industrial segment sells products to both original equipment manufacturers and distributors who serve the replacement markets in manufacturing, packaging, processing, transportation, mobile construction, refrigeration and air conditioning, agricultural and military machinery, and equipment industries. The Aerospace Systems segment offers products primarily in the commercial and military aerospace markets to both OEMs and to end users for spares, maintenance, repair, and overhaul. The company was founded by Arthur L. Parker in 1918 and is headquartered in Cleveland, OH.

Parker-Hannifin Corp.

Parker-Hannifin ($PH) is trending following its strategic acquisition of Filtration Group for over $9 billion, a move anticipated to significantly expand its market leadership and boost future earnings. This major corporate development, combined with continued strong performance in its Aerospace Systems segment and its reputation as a "Dividend King," is fueling bullish analyst sentiment and investor discussion, despite some debates around its current valuation.

ConocoPhillips is an exploration and production company, which engages in the exploration, production, transport, and marketing of crude oil, bitumen, and natural gas. It operates through the following geographical segments: Alaska, Lower 48, Canada, Europe, Middle East, and North Africa, Asia Pacific, and Other International. The Alaska segment explores for, produces, transports and markets crude oil, natural gas and NGLs. The Lower 48 segment consists of operations located in the 48 contiguous U.S. states and the Gulf of Mexico. The Canada segment refers to oil sands development in the Athabasca Region of northeastern Alberta and a liquids-rich unconventional play in western Canada. The Europe, Middle East, and North Africa segment includes operations in the Norwegian sector of the North Sea, the Norwegian Sea, Qatar, Libya, Equatorial Guinea and commercial and terminalling operations in the U.K. The Asia Pacific segment focuses on explorations and product operations in China, Indonesia, Malaysia, and Australia. The Other International segment handles exploration activities in Columbia and Argentina. The company was founded by Isaac Elder Blake on November 25, 1875 and is headquartered in Houston, TX.

Conoco Phillips

ConocoPhillips is a key focus following its Marathon Oil acquisition, which enhances its low-cost U.S. shale portfolio and is projected to deliver over $1 billion in annual synergies. The community is actively discussing COP's strong Q4 earnings beat, substantial shareholder return commitments, and strategic moves in LNG and Arctic exploration. Investors are weighing these developments against volatile oil prices and geopolitical events, highlighting the company's long-term resilience.

Teladoc Health, Inc. engages in the provision of telehealthcare services using a technology platform via mobile devices, the Internet, video and phone. It operates through the following segments: Teladoc Health Integrated Care, BetterHelp, and Others. The Teladoc Health Integrated Care segment offers virtual medical services. The BetterHelp segment includes virtual mental health and other wellness services. The company was founded in June 2002 by George Byron Brooks, Michael Gorton, and Gary Wald and is headquartered in New York, NY.

Teladoc Health Inc

Teladoc Health is trending as discussions center on its strategic positioning to capitalize on the multi-billion dollar Rural Health Transformation Program and its new TytoCare integration, aiming to expand virtual care in underserved areas. Community sentiment is sharply divided, with many anticipating a significant long-term rebound driven by healthcare reform and AI innovation, while others express deep frustration over past financial performance, leadership decisions, and persistent stock underperformance. The conversation reflects a strong divergence between high conviction in a future turnaround and calls for greater accountability from management.

SPDR Series Trust - State Street SPDR S&P Oil & Gas Exploration & Production ETF

SPDR Oil & Gas Exploration & Production ETF

The oil and gas exploration and production sector, represented by XOP, is fueling vigorous community debate, with many investors actively accumulating on perceived dips amidst discussions of a suppressed physical market and surging global demand from emerging economies and data centers. Despite ongoing geopolitical uncertainties and varied economic forecasts, there's a strong contrarian belief that the sector is building towards a significant long-term breakout into the late 2020s.

KKR & Co., Inc. operates as an investment firm. It offers alternative asset management as well as capital markets and insurance solutions. The firm's business segments include Asset Management and Insurance Business. The Asset Management segment engages in providing private equity, real assets, credit and liquid strategies, capital markets, and principal activities. The Insurance Business segment offers retirement, life insurance and reinsurance solutions to clients across individual and institutional markets. The company was founded by Henry Kravis, George R. Roberts, and Jerome Kholberg on May 1, 1976 and is headquartered in New York, NY.

KKR & Co. Inc

KKR & Co. Inc.

KKR is trending amid its aggressive strategic expansion into high-growth sectors like digital infrastructure, real estate, and healthcare, underpinned by strong capital raising and robust earnings. The firm's continuous deal-making and positive analyst sentiment are fueling investor discussions about its long-term trajectory in alternative asset management. Community chatter highlights KKR's positioning in AI-related infrastructure and its transition to a diversified, permanent capital model, drawing comparisons to leading financial institutions.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Indaptus Therapeutics, Uipath, Trinity Biotech, Sable Offshore And McDonald's: Why These 5 Stocks Are On Investors' Radars Today

INDP, PATH, TRIB, SOC, MCD were among the stocks seen among investors on Tuesday, Dec. 23, 2025.read more...

<ul class="summary-bullets"><li>Trinity Biotech’s shares were up nearly 47% in Tuesday’s midday trade after the company announced that it had secured an order for nine million units of its TrinScreen HIV rapid diagnostic test.</li><li>Starfighters Space shares were down over 51% in Tuesday’s midday session, taking a breather after a massive 371% rally on Monday.</li><li>VisionWave shares were up nearly 8% in Tuesday’s midday trade after the company announced the issuance of a new patent that covers the systems and methods for real-time movement, position detection, and imaging technology.</li></ul>U.S. equities traded in the green on Tuesday noon amid optimism about a Santa Claus rally, with the Dow Jones Industrial Average, S&amp;P 500, and the Nasdaq Composite on course for their fourth consecutive winning session.Earlier in the day, the Bureau of Economic Analysis&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/us-gdp-q3-december-2025/cLep8gzREuU">reported</a> that the U.S. economy grew at an annualized rate of 4.3%, higher than the Dow Jones forecast of 3.2%, as&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/us-gdp-q3-december-2025/cLep8gzREuU">cited</a> by MarketWatch.The&nbsp;<a href="https://stocktwits.com/symbol/SPY">SPDR S&amp;P 500 ETF</a> (SPY), which mirrors the S&amp;P 500 index, was up 0.28% at the time of writing, while the&nbsp;<a href="https://stocktwits.com/symbol/QQQ">Invesco QQQ Trust</a> (QQQ), which mirrors the Nasdaq 100 index, gained 0.25%. The&nbsp;<a href="https://stocktwits.com/symbol/DIA">SPDR Dow Jones Industrial Average ETF Trust</a> (DIA), which tracks the Dow Jones Industrial Average, rose 0.18%.<h2 class="st-heading-2">Here are the top stocks making the biggest moves in Tuesday’s midday trade:</h2><a href="https://stocktwits.com/symbol/NVO">Novo Nordisk AS (NVO)</a>Novo Nordisk shares were up more than 9% in Tuesday’s midday session after the company&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/novo-nordisk-stock-soars-after-hours-as-fda-greenlights-wegovy-pill-for-weightloss/cLeFw1kREu2">said</a> that its Wegovy pill for weight loss has been approved by the U.S. Food and Drug Administration (FDA), making it the first oral GLP-1 class drug for weight management approved by the agency.<a href="https://stocktwits.com/symbol/NVO">NVO stock</a> is down 39% year-to-date.<a href="https://stocktwits.com/symbol/TRIB">Trinity Biotech Plc. (TRIB)</a>Trinity Biotech’s shares were up nearly 47% in Tuesday’s midday trade after the company&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/why-did-trinity-biotech-stock-surge-nearly-50-in-premarket-today/cLepnI7REuv">announced</a> that it had secured an order for nine million units of its TrinScreen HIV rapid diagnostic test, scheduled for delivery in the fourth quarter (Q4) of 2025 and the first quarter (Q1) of 2026.<a href="https://stocktwits.com/symbol/TRIB">TRIB stock</a> is up 48% year-to-date.<a href="https://stocktwits.com/symbol/FJET">Starfighters Space Inc. (FJET)</a>Starfighters Space shares were&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/fjet-stock-takes-a-breather-post-massive-rally/cLepsN8REH7">down</a> over 51% in Tuesday’s midday session, taking a breather after a massive 371% rally on Monday. The company laid out its 2026 plans, stating that the convergence of government demand, growth in the commercial space segment, and public market access following its IPO positions it well.<a href="https://stocktwits.com/symbol/FJET">FJET stock</a> is up 56% year-to-date.<a href="https://stocktwits.com/symbol/VWAV">VisionWave Holdings Inc. (VWAV)</a>VisionWave shares were up nearly 8% in Tuesday’s midday trade after the company announced the issuance of a new patent that covers the systems and methods for real-time movement, position detection, and imaging technology.<a href="https://stocktwits.com/symbol/VWAV">VWAV stock</a> is up 263% year-to-date.<a href="https://stocktwits.com/symbol/NOW">ServiceNow Inc. (NOW)</a>ServiceNow shares were down nearly 3% in Tuesday’s midday session after the company&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/service-now-acquires-armis-in-7-75-billion-deal-to-strengthen-ai-powered-security-platform/cLepYSLREHb">announced</a> the acquisition of cybersecurity startup Armis in a $7.75 billion deal as it looks to bolster its offerings amid rising threats due to the expanding use of AI.<a href="https://stocktwits.com/symbol/NOW">NOW stock</a> is down 28% year-to-date.Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/fjet-stock-takes-a-breather-post-massive-rally/cLepsN8REH7">FJET Stock Takes A Breather Post Massive Rally – Starfighters Space Releases 2026 Plans After Stock Market Debut</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

A bull statue and a bear statue stand outside the Frankfurt Stock Exchange on April 7, 2025 in Frankfurt, Germany

Novo Nordisk, Trinity Biotech, Starfighters Space, VisionWave, ServiceNow: Stocks Making The Biggest Moves Today

Novo Nordisk shares were up more than 9% in Tuesday’s midday session after the company said that the U.S. FDA has approved its Wegovy pill for weight loss.

Equity

<ul class="summary-bullets"><li>Trinity posted a 32% sequential increase in third-quarter revenue to $14.3 million, driven by a $2.1 million increase in rapid HIV test sales.</li><li>The company entered into new financing agreements with funds managed by Perceptive Advisors.</li><li>The deal includes $5 million in new term-loan funding and up to $60 million in elective equitization capacity.</li></ul>Trinity Biotech (TRIB) shares surged nearly 50% in premarket trading on Tuesday, after the company said it had secured an order for 9 million units of its TrinScreen HIV rapid diagnostic test.The WHO-prequalified rapid diagnostic test is designed for high-volume screening programs and will be produced through the company’s recently approved outsourced manufacturing process. Trinity Biotech expects to fulfil the order across the fourth quarter of 2025 and the first quarter of 2026, with the contract set to support revenue growth.<a href="https://stocktwits.com/symbol/TRIB">Trinity Biotech</a> also posted a 32% sequential increase in third-quarter revenue to $14.3 million, driven by a $2.1 million increase in rapid HIV test sales, while adjusted EBITDA improved to a $0.5 million profit from a $2.1 million loss in Q2.The company said it continues to advance its transformation plan after securing key regulatory approvals, including WHO authorization to outsource production of its Uni-Gold HIV rapid test. These milestones are expected to drive efficiency gains and support rising adjusted EBITDA through the first half of 2026."Our operating and financial improvement in Q3 2025 was encouraging, in particular the achievement of positive Adjusted EBITDA. This gives us confidence that our Comprehensive Transformation Plan is on track and, when combined with our exciting innovation agenda, leaves the business well positioned for further progress in 2026,” said John Gillard, CEO of Trinity Biotech. &nbsp;<h2 class="st-heading-2">Trinity's Financing Plans</h2>Trinity Biotech also entered into new financing agreements with funds managed by Perceptive Advisors to strengthen liquidity and improve capital structure flexibility.&nbsp;The deal includes $5 million in new term-loan funding and up to $60 million in elective equitization capacity, which could lower debt and interest costs. The agreements also introduce equity-based settlement options for certain obligations, supporting Trinity Biotech’s long-term growth and investment plans.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Retail sentiment flipped to 'extremely bullish' from 'extremely bearish' a day earlier, amid 'extremely high' message volumes.<img src="https://news.stocktwits-cdn.com/TRIB_png_e777e3d7ee.webp" alt="TRIB.png">One user sees $1.75 as a key resistance point.<stembedurl>https://stocktwits.com/TeamBullish/message/639966430</stembedurl>Year-to-date, the stock has gained 43%.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Why Did Trinity Biotech Stock Surge Nearly 50% In Premarket Today?

Trinity Biotech (TRIB) shares surged nearly 50% in premarket trading on Tuesday, after the company said it had secured an order for 9 million units of its TrinScreen HIV rapid diagnostic test.

The company secured an order for 9 million units of its TrinScreen HIV rapid diagnostic test.

Trinity Biotech's Redesigned CGM Sensor Favored by New Clinical Data

TRIB's needle-free CGM+ sensor shows accurate 15-day results with no calibration, slashing costs and boosting access.

Trinity Biotech&nbsp;notched its best session on record on Thursday after its New York reference laboratory received approval from the New York State Department of Health to begin offering the FDA-cleared PreClara Ratio biomarker test for assessing the risk of preeclampsia.&nbsp;Shares of Trinity Biotech soared 89.1% to $1.9 on Thursday, marking its best session since the company’s launch in 1992, before sliding 16% to $1.6 in after-hours trading. Additionally, trading volume in Trinity surged to 208.5 million shares on Thursday, more than 1,160 times its average daily volume of 178,948.The service, which has a planned release in the third quarter (Q3) of 2025, is expected to support clinicians in making more rapid and informed decisions for patients hospitalized with hypertensive disorders of pregnancy, a complex set of conditions that impacts approximately 500,000 women annually in the U.S.&nbsp;The test, by estimating the risk of progression to severe preeclampsia, can enable earlier and more precise interventions.&nbsp;Research published in March estimated the potential to achieve more than $10 million in neonatal cost savings per 1,000 patients with the test as part of standard care, largely due to a reduction in preterm births and NICU days.The approval also paves the way for Trinity's expected launch of PrePsia, its proprietary technology that screens for preeclampsia risk earlier in pregnancy.&nbsp;Preeclampsia is estimated to affect 5–8% of pregnancies. The condition is a major driver of maternal and neonatal complications in the U.S., accounting for approximately 11% of maternal deaths and 15% of premature births.The PreClara Ratio is designed for use alongside other laboratory tests and clinical assessments in women between 23 and nearly 35 weeks of pregnancy who are hospitalized with hypertensive disorders.&nbsp;It calculates a ratio from specific blood test results to estimate the short-term risk of developing severe preeclampsia.On Stocktwits, retail sentiment for Trinity Biotech was ‘extremely bullish’ amid a 7,211% surge in 24-hour message volume.One user remarked that they expected Trinity Biotech to climb back over $3.00 the next day, urging others to “buy the dips and hold,” adding that all short shares were accounted for and the stock “can rip and halt like it did today.”&nbsp;<stembedurl>https://stocktwits.com/Magicians/message/625281470</stembedurl>Another user speculated that the sharp rise could be followed by a dilution announcement, noting the stock was now “going down on huge volume.”&nbsp;<stembedurl>https://stocktwits.com/Huskersnsaints/message/625247540</stembedurl>A third user predicted it could “easily break $4.00” going into the next session, recommending buying at market price and holding.<stembedurl>https://stocktwits.com/Magicians/message/625225289</stembedurl>Trinity Biotech’s stock has more than doubled so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Shares of Trinity Biotech (TRIB) soared 89.1% to $1.9 on Thursday, marking its best session since the company’s launch in 1992. (Photo credit: Getty Images)

Trinity Biotech Stock Marks Best Day Ever On New York Greenlight For Pregnancy Risk Test; Retail Sees More Upside

Trading volume in Trinity Biotech spiked to more than 1,160 times its daily average after regulators cleared the PreClara Ratio test, which helps doctors identify pregnant patients at risk of developing severe preeclampsia.

Three nano-cap healthcare stocks drew massive attention from retail investors on Stocktwits Tuesday, though not all for positive reasons.Trinity Biotech (<a href="https://stocktwits.com/symbol/TRIB">TRIB</a>)&nbsp;Shares of the medical diagnostic products maker saw a staggering 15,550% jump in retail message volume after the company released “compelling” results from a study on its next-generation continuous glucose monitoring system.&nbsp;The device, designed for real-time diabetes management, demonstrated superior signal quality, accuracy, and consistency in a trial involving 30 diabetic participants.&nbsp;The system features a reusable applicator and rechargeable wearable transmitter, reducing costs by eliminating disposable components.&nbsp;Trinity said it remains on track to seek regulatory approval in the EU by 2025 and the U.S. by 2026.&nbsp;Shares fell over 13% premarket Wednesday.Silexion Therapeutics (<a href="https://stocktwits.com/symbol/SLXN">SLXN</a>)&nbsp;The cancer-focused biotech firm’s ticker saw a 9,060% surge in retail message volume as its stock more than doubled Tuesday following promising preclinical data for its tumor drug candidate SIL-204.&nbsp;The company reported that the extended-release formulation of SIL-204 reduced tumor growth by more than 50% after 30 days, with around 50% of tumors showing complete necrosis in human pancreatic models.&nbsp;Additionally, an injectable version of the drug candidate showed tumor growth inhibition in metastatic pancreatic mouse models.&nbsp;The stock continued its rally, gaining over 70% premarket Wednesday.Sharps Technology (<a href="https://stocktwits.com/symbol/STSS">STSS</a>)&nbsp;The medical packaging firm experienced a 6,233% surge in retail message volume, but for the wrong reasons.&nbsp;Shares plunged nearly 70% to a record low on Tuesday after the company announced a $20 million public offering of 14,285,714 Common Units.&nbsp;Each unit consists of one share of common stock, one Series A warrant, and one Series B warrant, priced at $1.40 per unit, a 4.1% discount to Monday’s close.&nbsp;The company said the proceeds would be used for general corporate purposes and working capital.&nbsp;The stock continued to slide, down over 2% premarket Wednesday.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Stockbroker analyzing financial stock market with reflection on eyeglasses. Photo via Westend61 on Getty Images

TRIB, SLXN, STSS: Why Retail Chatter On 3 Nano-Cap Healthcare Stocks Exploded Over 6000%

“Compelling” results from a study, promising pre-clinical data and a public offering got Stocktwits investors buzzing on Tuesday.

Trinity Biotech Plc engages in the development, manufacture, and marketing of medical diagnostic products for the clinical laboratory and point-of-care segments of the diagnostic market. It operates through the Americas and Rest of World geographical segments. The company was founded by Ronan O'Caoimh and Denis R. Burger in June 1992 and is headquartered in Bray, Ireland.

Current Price	$0.791
Prev Close	$0.82
Open	$0.81
Dividend Yield	0.00%
50-Day Moving Average	$0.9592
Beta	0.50
Avg. Volume	65,131.37
PE Ratio	-0.31

52-Week High	$3.44
52-Week Low	$0.48
Market Capitalization	$14.74M
EPS (Annual)	-$1.77
Price to Book	-0.30
Revenue Per Employee	$153,232.58
Enterprise Value/EBITDA	N/A

TRIB
Trinity Biotech plc

Feed

News

Sentiment

Fundamentals

Info

Latest TRIB News

TRIBTrinity Biotech plc